Heart, Lung and Vascular Institute, Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH 45267
Heart, Lung and Vascular Institute, Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH 45267.
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11731-11736. doi: 10.1073/pnas.1821660116. Epub 2019 May 29.
Phosphorylation of cardiac myosin binding protein-C (cMyBP-C) accelerates cardiac contractility. However, the mechanisms by which cMyBP-C phosphorylation increases contractile kinetics have not been fully elucidated. In this study, we tested the hypothesis that phosphorylation of cMyBP-C releases myosin heads from the inhibited super-relaxed state (SRX), thereby determining the fraction of myosin available for contraction. Mice with various alanine (A) or aspartic acid (D) substitutions of the three main phosphorylatable serines of cMyBP-C (serines 273, 282, and 302) were used to address the association between cMyBP-C phosphorylation and SRX. Single-nucleotide turnover in skinned ventricular preparations demonstrated that phosphomimetic cMyBP-C destabilized SRX, whereas phospho-ablated cMyBP-C had a stabilizing effect on SRX. Strikingly, phosphorylation at serine 282 site was found to play a critical role in regulating the SRX. Treatment of WT preparations with protein kinase A (PKA) reduced the SRX, whereas, in nonphosphorylatable cMyBP-C preparations, PKA had no detectable effect. Mice with stable SRX exhibited reduced force production. Phosphomimetic cMyBP-C with reduced SRX exhibited increased rates of tension redevelopment and reduced binding to myosin. We also used recombinant myosin subfragment-2 to disrupt the endogenous interaction between cMyBP-C and myosin and observed a significant reduction in the population of SRX myosin. This peptide also increased force generation and rate of tension redevelopment in skinned fibers. Taken together, this study demonstrates that the phosphorylation-dependent interaction between cMyBP-C and myosin is a determinant of the fraction of myosin available for contraction. Furthermore, the binding between cMyBP-C and myosin may be targeted to improve contractile function.
肌球蛋白结合蛋白 C(cMyBP-C)的磷酸化可加速心肌收缩。然而,cMyBP-C 磷酸化增加收缩动力学的机制尚未完全阐明。在这项研究中,我们检验了以下假设:cMyBP-C 的磷酸化将肌球蛋白头部从抑制的超松弛状态(SRX)中释放出来,从而确定可用于收缩的肌球蛋白分数。使用具有 cMyBP-C 三个主要可磷酸化丝氨酸(丝氨酸 273、282 和 302)的各种丙氨酸(A)或天冬氨酸(D)取代的小鼠来解决 cMyBP-C 磷酸化与 SRX 之间的关联。在去皮的心室制剂中单核苷酸转换表明,磷酸模拟 cMyBP-C 使 SRX 不稳定,而磷酸化缺失的 cMyBP-C 对 SRX 具有稳定作用。令人惊讶的是,发现丝氨酸 282 位点的磷酸化在调节 SRX 方面起着关键作用。用蛋白激酶 A(PKA)处理 WT 制剂可减少 SRX,而在不可磷酸化的 cMyBP-C 制剂中,PKA 没有可检测到的作用。具有稳定 SRX 的小鼠表现出减少的力产生。具有减少的 SRX 的磷酸模拟 cMyBP-C 表现出张力重新发展的增加速率和对肌球蛋白的减少结合。我们还使用重组肌球蛋白亚片段-2 来破坏 cMyBP-C 和肌球蛋白之间的内源性相互作用,并观察到 SRX 肌球蛋白的群体显著减少。该肽还增加了去皮纤维中的力产生和张力重新发展的速率。总之,这项研究表明,cMyBP-C 和肌球蛋白之间的磷酸化依赖性相互作用是可用于收缩的肌球蛋白分数的决定因素。此外,cMyBP-C 和肌球蛋白之间的结合可能被靶向以改善收缩功能。